Table 3—

Incidence (percentage of patients reporting one or more hypoglycemic episode) and percentage risk reduction of symptomatic, nocturnal, and nonnocturnal hypoglycemia and severe, severe nocturnal, and severe nonnocturnal hypoglycemia in patients receiving insulin glargine versus NPH insulin

Type of symptomatic hypoglycemiaInsulin glargine (% of patients)NPH insulin (% of patients)PInsulin glargine significant % risk reduction
Overall documented54.261.20.000611
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)46.053.30.000414
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)29.937.00.000219
Nocturnal documented28.438.2<0.000126
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)23.933.9<0.000129
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)16.323.1<0.000129
Nonnocturnal documented49.651.70.4642
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)40.142.90.2553
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)22.825.40.1545
Severe documented1.42.60.044246
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)1.12.00.1089
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)0.91.50.1735
Severe nocturnal documented0.71.70.023159
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)0.61.50.041660
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)0.51.30.046162
Severe nonnocturnal documented0.80.90.7296
    Plasma glucose ≤72 mg/dl (≤4.0 mmol/l)0.60.60.9042
    Plasma glucose ≤56 mg/dl (≤3.1 mmol/l)0.40.30.4669